Literature DB >> 8127537

Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors.

L Valentin1, P Sladkevicius, K Marsàl.   

Abstract

OBJECTIVE: To compare the ability of transvaginal color and spectral Doppler and that of gray-scale ultrasound examination to discriminate between benign and malignant extrauterine pelvic tumors.
METHODS: One hundred forty-nine consecutive women scheduled for laparotomy because of an extrauterine pelvic mass underwent ultrasound examination, including color and spectral Doppler techniques, within 8 days before a planned operation. Based on the gray-scale ultrasound image, each tumor was classified as a unilocular cyst, multilocular cyst, unilocular cyst with solid parts, multilocular cyst with solid parts, or solid tumor. Doppler signals of the maximum blood flow velocity of tumor vessels were evaluated for pulsatility index (PI) and peak systolic and time-average maximum velocity. The results of gray-scale imaging and Doppler velocimetry were related to the final diagnosis, which in most cases was based on histology of the specimen.
RESULTS: None of the 88 unilocular or multilocular cysts without solid parts were malignant, compared to 28 malignancies (46%) among the 61 tumors with solid components. The PI was significantly lower, and the peak systolic and time-average maximum blood flow velocities significantly higher, in the malignant than in the benign tumors. However, this was true only of the multilocular cysts with solid parts; the PI and blood flow velocity results overlapped completely between benign and malignant solid tumors. According to receiver operating characteristic curves, the ultrasound morphology of the tumors was a better discriminator between benign and malignant tumors than any of the Doppler variables. Ultrasound morphology correctly identified all the malignant tumors, with a false-positive rate of 27%. Discrimination was slightly improved if PI and blood flow velocity were used for discriminating between benign and malignant multilocular cysts with solid parts. With this approach, all the malignant tumors were detected with a false-positive rate of 17-23%, depending on which Doppler variable and which cutoff level was used.
CONCLUSION: The present technique of Doppler velocimetry has a limited contribution to the differential diagnosis of extrauterine pelvic tumors.

Entities:  

Mesh:

Year:  1994        PMID: 8127537

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

2.  [Endoscopic surgery: from the possible to the sensible].

Authors:  B Schüssler
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

3.  [Ultrasonographic clarification of adnexal findings].

Authors:  H J Prömpeler
Journal:  Radiologe       Date:  2011-07       Impact factor: 0.635

4.  Doppler ultrasound: a good and reliable predictor of ovarian malignancy.

Authors:  Dharita Shah; Sandip Shah; Jay Parikh; C J Bhatt; Kavita Vaishnav; D V Bala
Journal:  J Obstet Gynaecol India       Date:  2012-11-10

5.  Selected adnexal cystic masses in postmenopausal women can be safely managed by laparoscopy.

Authors:  Jeong-Won Lee; Chul Jung Kim; Ji Eun Lee; Sun-Joo Lee; Byoung Gie Kim; Je-Ho Lee; Duk-Soo Bae; Chang-Soo Park
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

6.  Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses.

Authors:  Nidhi Sehgal
Journal:  J Midlife Health       Date:  2019 Jan-Mar

7.  Prospective revalidation of IOTA "two-step", "alternative two-step" and "three-step" strategies for characterization of adnexal masses - An Indian study focussing the radiology context.

Authors:  Shabnam Bhandari Grover; Sayantan Patra; Hemal Grover; Pratima Mittal; Geetika Khanna
Journal:  Indian J Radiol Imaging       Date:  2020-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.